Alkermes plc (ALKS) Tops Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2016 and Provides Financial Expectations for 2017
February 15, 2017 7:00 AM ESTRecord Revenues of $746 Million, GAAP Loss Per Share of $1.38 and Non-GAAP Loss Per Share of $0.07 Reported for 2016
VIVITROL® Net Sales Grew by 45% Year-Over-Year to $209.0 Million
2017 Total Revenues Expected to Grow by Approximately 20%, Driven by Continuing Volume Growth of VIVITROL and ARISTADA®
Company Plans to Submit New Drug Application for ALKS 5461 in 2017
DUBLIN--(BUSINESS WIRE)--... More
